All lobbying filings

THE MCMANUS GROUP

Lobbying for ARDELYX · BioPharma Company

Filing 1st Quarter - Report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 21, 2025

Income

$20,000.00

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 1

Medicare/Medicaid

Issues related to the 2025 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Final Rule (CMS-105-F), specifically the inclusion of oral-only drugs in the ESRD PPS Bundled Payment.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.